SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
11.05
+0.01 (0.09%)
At close: Aug 11, 2026, 4:00 PM EDT
11.06
+0.01 (0.06%)
After-hours: Aug 11, 2026, 7:59 PM EDT
SLS Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
2.17B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.00M | -6.60M | -86.84% |
| Dec 31, 2021 | 7.60M | 5.70M | 300.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ADMA Biologics | 512.28M |
| Vericel | 306.30M |
| Nuvation Bio | 169.90M |
| Septerna | 98.88M |
| Mesoblast | 65.38M |
| Ocular Therapeutix | 52.06M |
| Stoke Therapeutics | 27.59M |
| Taysha Gene Therapies | 7.47M |
SLS News
- 10 hours ago - SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 19 hours ago - SELLAS Life Sciences Group Quarterly report: Q2 2026 - Filings
- 19 hours ago - SELLAS Life Sciences Group Earnings release: Q2 2026 - Filings
- 25 days ago - Sellas Life Sciences rises 11.0% - TheFly
- 25 days ago - Sellas Life Sciences rises 10.2% - TheFly
- 5 weeks ago - Sellas Life Sciences price target raised to $25 from $10 at Alliance Global - TheFly
- 5 weeks ago - Sellas Life Sciences falls -11.0% - TheFly
- 6 weeks ago - Sellas Life Sciences falls -8.9% - TheFly